Chemical Nature and Mechanism of Action
Chemically, the drug is N-acetyl-L-cysteine.
The primary pharmacological property of the drug is its mucolytic effect, which occurs via two pathways:
- Direct effect on sputum structure. The molecule contains free sulfhydryl (-SH) groups. These groups are capable of cleaving disulfide bonds in the proteoglycans of bronchial secretions. This leads to the depolymerization of macromolecules, sharply decreasing sputum viscosity and adhesiveness.
- Additional effects. The drug stimulates the secretion of mucous cells, increasing the total volume of secretions. Additionally, it causes fibrin lysis, which is particularly important in the presence of purulent or fibrinous sputum.
Systemic Effects: Antioxidant and Antidote
In addition to its effects on the respiratory tract, the drug possesses important systemic properties:
- Antioxidant and anti-inflammatory action. The compound actively suppresses the formation of free radicals, significantly reducing the intensity of the inflammatory response directly within the bronchial tree.
- Detoxifying action. The substance stimulates the synthesis of glutathione, a critical factor in endogenous detoxification. For this reason, it is used in toxicology as an antidote for acetaminophen (paracetamol) overdose, acting as a glutathione donor to prevent severe hepatotoxicity.
Pharmacokinetics and Administration Routes
The drug is available in various pharmaceutical formulations, determining its route of administration:
- Enteral: orally as effervescent tablets or granules.
- Parenteral: intramuscularly and intravenously.
- Local and inhalational: via inhalation or intratracheal instillation.
Following oral administration, absorption is rapid and complete. However, the final systemic bioavailability remains low (not exceeding 10%). This is due to a pronounced first-pass effect in the liver, where the molecule is deacetylated into regular cysteine.
Indications, Contraindications, and Safety
Main indications for use:
- Inflammatory respiratory conditions (chronic bronchitis, tracheobronchitis, pneumonia).
- Bronchial asthma and chronic obstructive pulmonary disease (COPD).
- Acetaminophen poisoning.
Safety profile and side effects: Therapy may cause dyspeptic symptoms (nausea and vomiting), allergic reactions such as urticaria, and tinnitus.
Absolute contraindications:
- Peptic ulcer disease.
- Predisposition to pulmonary hemorrhage.
- Liver and kidney disorders, adrenal dysfunction.
- Pregnancy and lactation.
Drug Interactions
When prescribing, it is essential to consider pharmaceutical and pharmacological compatibility:
- Pharmaceutical incompatibility. Mixing the drug in the same syringe or solution with antibiotics and proteolytic enzymes is strictly prohibited, as it leads to their inactivation. Contact with rubber and metals (copper, iron) causes the formation of sulfides and a characteristic odor.
- Pharmacokinetic interaction. The agent decreases the absorption of certain antibiotics (penicillins, cephalosporins, tetracyclines). An interval of at least two hours must be maintained between their administrations.
- Pharmacodynamic interaction. The drug can potentiate the vasodilating effect of nitroglycerin.